Fresenius buys Dabur's Indian oncology business

Fresenius is to acquire India's Dabur Pharma for $219 million giving it access to a portfolio of cancer treatment drugs and a supply of raw materials.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES